Home
Search
Toolkit for Advocates

Toolkit for Advocates

We’ve made it easier for you to access information and share content about biotechnology and how it improves our daily lives, from prescription medications and a resilient food supply to renewable energy and sustainable bioprocessing materials. The information you discover can easily be shared on Twitter, Facebook and LinkedIn.

  • Show All
Results
PDF
Patients Pay. Middlemen Take. Innovation Loses.
FLIP
Half of every dollar spent on medicines is lost to supply chain markups.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Importing International Drug Pricing Threatens U.S. Patient Access
FLIP
Policies Like Most Favored Nation Pricing and International Reference Pricing Would: Hurt American Patients
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Investor Survey
FLIP
The science driving medical innovation is advancing at a breathtaking pace, bringing hope to patients in the United States and worldwide.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
About BIO
FLIP
BIO is the premier biotechnology advocacy organization representing biotech companies, industry leaders, and state biotech associations in the United States and more than 35 countries around the globe.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
The Cost of PRV Inaction
FLIP
Failing to Reauthorize the Rare Pediatric Disease Priority Review Voucher Program (PRV).
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
ORPHAN Cures Act: Protecting New Treatments for Patients with Rare Diseases
FLIP
The ORPHAN Cures Act reaffirms Congress’s strong, bipartisan commitment to protect the research and development of new treatments for patients with rare diseases
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
How Vaccines Are Made and Monitored
FLIP
Prior to human clinical trials, new vaccines undergo extensive lab testing, often for several years.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Understanding Messenger RNA Vaccines in Humans & Animals
FLIP
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Help Ensure Providers Have Access to All Approved Immunizations
FLIP
Providers are best equipped to choose the right vaccine for their patients. Vaccines that prevent the same disease may have clinical, dosing, and/or presentation differences (e.g., fully-liquid or non-fully-liquid vaccines requiring reconstitution). Providers develop individual preferences based on their specialized knowledge and the specific healthcare needs of their patients.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Engaging in the Federal Rulemaking Process; How patient advocacy groups can get involved in the rulemaking process
FLIP
Learn how patient advocacy groups can get involved in the federal rulemaking process.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
The Orphan Cures Act
FLIP
The ORPHAN Cures Act is bipartisan legislation that would maintain existing incentives and boost research into new treatments for the 30 million Americans currently suffering from one of more than 7,000 rare diseases. The bill would achieve this by amending the Inflation Reduction Act’s harmful orphan drug exclusion and incentivizing critical follow-on investment into rare disease drug development.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Patient Benefits from 340B Have Eroded
FLIP
Congress created the 340B Drug Discount Program to help uninsured and vulnerable patients gain access to affordable prescription drugs and services. Over the years this program has expanded well past the original intent of Congress and now patients are not seeing the benefits they deserve.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
DSH Hospital Abuse the 340B Drug Pricing Program
FLIP
Many hospitals in the 340B Program are exploiting lax eligibility criteria and program guardrails to profit from the substantial 340B discounts that were intended to ensure low-income access to discounted prescription drugs and services. 
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
How DSH Hospitals Abuse the 340B Drug Pricing Program
FLIP
How DSH Hospitals Abuse the 340B Drug Pricing Program
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
340B Backgrounder
FLIP
In 1992, with the support of the biopharmaceutical industry, Congress created the 340B Drug Pricing Program to help uninsured and vulnerable patients. As part of the law, drug manufacturers provide significant discounts on outpatient medicines and treatments to select eligible health care “covered entities” — often referred to as safety- net providers.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Use of Human Cell Lines in Critical Vaccines and Therapies
FLIP
To develop a vaccine that can be produced on a large scale, researchers must grow viruses or bacteria in large quantities and with great consistency.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Vaccine Development, Licensure & Safety
FLIP
The creation of a vaccine involves scientists and medical experts from around the world, and it usually requires 10 to 15 years of research before the vaccine is made available to the general public.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
Value of Vaccines: A Landmark Achievement
FLIP
Vaccination is often cited among the 10 greatest public health achievements of the 20th century. Only access to safe and clean water has had a larger effect on human health by preventing disease and extending lifespans.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
The U.S. Bioscience Industry Fosters Innovation and Drives America’s Economy Forward
FLIP
The bioscience industry and its supporting ecosystem drive bold innovations to address unmet human needs in the U.S. and around the world, including developing new breakthrough therapies that treat deadly diseases. The collective efforts of the industry and our public and private stakeholders have met the challenges of the COVID pandemic head-on, while lessening the impacts of climate change and nourishing a growing global population.
DOWNLOAD PDF
VIEW PDF
FLIP
PDF
IRA Drug Negotiation: At a Glance
FLIP
Maximum Fair Price: A manufacturer of a drug selected for negotiation will be required to offer a “maximum fair price” for the selected drug with respect to Medicare beneficiaries.
DOWNLOAD PDF
VIEW PDF
FLIP